[CLSTR]
< Back to all clusters
[HEALTH] · United States, United Kingdom, Germany, Italy · 4 sources

started · updated

CBL-514 injectable drug targets fat cells to reduce abdominal fat

CBL-514 weight loss drug fat cell apoptosis visceral fat obesity therapy

Researchers are developing a new injectable weight-loss drug, CBL-514, which targets fat cells directly by triggering programmed cell death, or apoptosis. Unlike GLP-1 medications such as Ozempic or Wegovy, which primarily function by suppressing appetite and slowing digestion, CBL-514 acts locally at the site of administration to destroy fat tissue.

Data from Phase 2 clinical trials, presented at the European Association for the Study of Diabetes meeting in Milan, indicates the drug is effective at reducing both subcutaneous fat (located under the skin) and visceral fat (the dangerous fat surrounding internal organs). In these trials, approximately 70 percent of participants saw a reduction of at least 150 mL of subcutaneous fat within eight weeks.

Experts, including those from the University of Alabama, suggest the drug could offer both cosmetic benefits, such as a flatter stomach, and significant health improvements by reducing visceral fat, which is linked to type 2 diabetes and cardiovascular disease. Preliminary findings also suggest that using CBL-514 alongside tirzepatide may enhance weight-loss results. Two Phase 3 clinical trials are expected to follow.

Entities

CBL-514 · European Association for the Study of Diabetes · Timothy Garvey · University of Alabama

Claims

What the coverage asserts, and how many sources carry each claim.

Sources

A new drug allows you to lose your gut without Ozempic or surgery! [1470kyyw.com]
New weight-loss drug could give you a ‘flatter stomach’ in mere weeks — and unlike Ozempic, it targets belly fat directly [offthepress.com]
CBL-514: Neue Injektion soll gezielt Fettzellen töten und VAT senken [www.it-boltwise.de]
'Remarkable' targeted new fat jab can help users shed pounds in months [www.dailymail.com]